TuesdayJul 23, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have this strong group of individuals join…

Continue Reading

TuesdayJul 23, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

CNM-Au8(R) works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health Clene has conducted several clinical trials to evaluate the safety and efficacy of CNM-Au8 in neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for CNM-Au8 to treat ALS Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative…

Continue Reading

MondayJul 22, 2024 10:00 am

Study Uncovers Ancient Egyptian Attempts to Surgically Remove Brain Cancer

New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant tumors. The researchers found that one skull, which belonged to a female about 50 years of age, had healed injuries on the cranium that may have been made by a sharp object. This evidence suggests that the woman survived because of a treatment and some post-traumatic care administered. Another skull, belonging to a man in his 30s, also had…

Continue Reading

FridayJul 19, 2024 10:00 am

Survey Shows Most US States Offer Medicare Advantage to Retirees

A new survey has determined that the share of employers who still provide health benefits to retirees has been decreasing over time, reaching 21% as of last year. The survey was carried out by Kaiser Family Foundation (KFF), a leading health policy organization in the United States. The survey’s objective was to examine the extent to which states were offering health benefits to eligible retirees under Medicare, via Medicare Advantage arrangements. This analysis was based on KFF’s review of employee-retirement-system sites for different states. The survey determined that almost all the states along with the District of Columbia offer health…

Continue Reading

FridayJul 19, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease

The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients Following the announcement of these positive results, the company’s stock price surged by 76% The data revealed that while 12% of Parkinson’s Disease patients showed cognitive decline, buntanetap not only halted this decline but also led to improvements Annovis held a webcast to go over the results in more depth, which is available for replay on the company’s website Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s…

Continue Reading

ThursdayJul 18, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction

Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a treatment for ALS via the accelerated approval process The briefing book includes new post-hoc analyses of data from completed clinical trials and addresses comments made by the FDA during a previous meeting in late 2023 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage…

Continue Reading

WednesdayJul 17, 2024 10:00 am

Women with Autism Have Higher Odds of Being Misdiagnosed with BPD

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that has been identified to occur at different levels of severity. Patients with this disorder are sometimes misdiagnosed, because its symptoms overlap with other disorders. It is said that women are less likely to be accurately diagnosed with autism during their lifetimes, with most being misdiagnosed with borderline personality disorder (BPD) or other disorders before they are diagnosed with autism. A possible explanation is that young girls learn how to fit in and get along with others early. Focusing on social interaction may enable them to camouflage their autism symptoms, which keeps…

Continue Reading

WednesdayJul 17, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is…

Continue Reading

MondayJul 15, 2024 10:00 am

Study Suggests Vitamin B Deficiency Could Be Pivotal in Parkinson’s Disease

Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease. This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubling since 1990. The risk of developing this condition heightens with age; in addition, men are 50% more likely than women to develop the disease. Other risk factors include past traumatic brain injury, exposure to environmental toxin and genetics. Primary symptoms of the condition include muscle stiffness, tremors, impaired coordination and balance, gastrointestinal symptoms and emotional changes, among others. Prior…

Continue Reading

FridayJul 12, 2024 10:00 am

Study Explores Starving Malignant Cells to Boost Immunotherapy, Improve DNA Damage

Prostate cancer is challenging to treat, especially when the disease progresses to a castrate-resistant metastatic state. Conventional treatments, such as hormonal treatments, radiotherapy and chemotherapy, fail most times because of acquired resistance, off-target effects and toxicities. It is well-known that amino acids perform important metabolic functions. While normal cells have lower demand for amino acids, cancer cells exhibit high demand for amino acids because of increased demand for cellular building blocks and energy. Now a new study has determined that starving cancer cells may help improve immunotherapy response and increase damage to DNA, which in turn helps speed up death…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000